Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) saw unusually-high trading volume on Wednesday . Approximately 1,129,778 shares changed hands during mid-day trading, a decline of 4% from the previous session's volume of 1,179,263 shares.The stock last traded at $77.46 and had previously closed at $73.54.
Wall Street Analyst Weigh In
Several research analysts have recently commented on SRPT shares. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $163.00 target price on shares of Sarepta Therapeutics in a report on Tuesday, March 18th. Royal Bank of Canada cut their target price on Sarepta Therapeutics from $165.00 to $161.00 and set an "outperform" rating for the company in a research report on Thursday, February 27th. Scotiabank decreased their price target on Sarepta Therapeutics from $105.00 to $80.00 and set a "sector perform" rating on the stock in a research report on Thursday. HC Wainwright reaffirmed a "sell" rating and set a $75.00 price objective on shares of Sarepta Therapeutics in a research report on Wednesday. Finally, Piper Sandler dropped their target price on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an "overweight" rating for the company in a research report on Wednesday, November 27th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $167.41.
Check Out Our Latest Stock Report on SRPT
Sarepta Therapeutics Price Performance
The firm has a 50-day moving average price of $107.19 and a 200 day moving average price of $117.88. The stock has a market capitalization of $7.19 billion, a P/E ratio of 59.28 and a beta of 0.79. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84.
Insider Transactions at Sarepta Therapeutics
In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of the business's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total transaction of $248,203.24. Following the transaction, the director now directly owns 27,812 shares of the company's stock, valued at approximately $2,771,187.68. The trade was a 8.22 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 7.70% of the company's stock.
Institutional Trading of Sarepta Therapeutics
Several hedge funds and other institutional investors have recently made changes to their positions in SRPT. Wealth Enhancement Advisory Services LLC boosted its position in Sarepta Therapeutics by 4.9% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 4,699 shares of the biotechnology company's stock worth $571,000 after purchasing an additional 218 shares during the last quarter. GF Fund Management CO. LTD. purchased a new position in Sarepta Therapeutics during the fourth quarter valued at $244,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Sarepta Therapeutics by 11.6% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 299,301 shares of the biotechnology company's stock valued at $36,392,000 after acquiring an additional 31,098 shares during the last quarter. Woodline Partners LP purchased a new stake in Sarepta Therapeutics in the 4th quarter worth $5,713,000. Finally, Vestal Point Capital LP bought a new position in shares of Sarepta Therapeutics during the 4th quarter valued at about $30,398,000. Hedge funds and other institutional investors own 86.68% of the company's stock.
Sarepta Therapeutics Company Profile
(
Get Free Report)
Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.
Recommended Stories
Before you consider Sarepta Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sarepta Therapeutics wasn't on the list.
While Sarepta Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
